Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine. The two studies included in total 1,635 participants and investigated insulin degludec compared to...

Kamada, announced positive preliminary interim results from a Phase I/II clinical trial of D1-AAT, which includes the Alpha 1 protein, for the treatment of type 1 diabetes. D1-AAT may slow the progression of the type 1 diabetes, and may greatly reduce or eliminate, the need for insulin. This would stabilize the condition of diabetics...

JDRF-funded scientists from the Indiana University School of Medicine have found that a specific type of cellular stress takes place in pancreatic beta cells before the onset of type 1 diabetes and this stress response in the beta cell may in fact help ignite the autoimmune attack. These findings shed an entirely new light into the...

The presence of   gastric H. pylori bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c) and type 2 diabetes, according to a study in the Journal of Infectious Diseases.  Yu Chen, PhD, and Martin Blaser, MD, at NYU School of Medicine, part of NYU Langone Medical Center, cross-analyzed data from participants...

The goal of a therapy for type 1 diabetes is restoration of regulated insulin secretion.  A newly published study, conducted by Chutima Talchai, PhD, and Domenico Accili, MD, professor of medicine at Columbia University Medical Center, found insulin secretion in unexpected place – the gut.  The researchers discovered that certain...

A new JDRF-funded study shows that many of the genes known to play a role in type 1 diabetes (T1D) are expressed in pancreatic beta cells, suggesting that the cell responsible for producing insulin may be playing a part in its own destruction to lead to T1D. Published in the March issue of PLoS Genetics, researchers in Belgium suggest...

A study conducted at Massachusetts General Hospital (MGH) has found that insulin production may persist for decades after the onset of type 1 diabetes.     In the study, led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, blood samples from 182 individuals with type 1 diabetes were evaluated using...

Novo Nordisk has decided to establish a type 1 diabetes research and development center in Seattle, Washington.  The unique concept behind the new center is to pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This will give the new center the necessary...

KalVista Pharmaceuticals (“KalVista”) and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease. Diabetic eye disease is one of the most common and most serious complications in people with type 1 diabetes (T1D). JDRF will...

One year after Osiris Therapeutics in partnership with JDRF started the Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in newly diagnosed type 1 diabetes patients, the company has released a statement providing an update on this groundbreaking trial. This first-of-its kind trial is testing...